
Phase 2a Clinical Data Show CuraSen Therapeutics’ CuraAX (CST-3056) Met Primary Endpoint Demonstrating Statistically Significant Improvement in Standing Systolic Blood Pressure in Patients with Neurogenic Orthostatic Hypotension (nOH)
SAN DIEGO--November 12, 2026--CuraSen Therapeutics, Inc., a biopharmaceutical company developing drug candidates for neurodegenerative diseases, today announced positive, exploratory Phase 2a data showing statistically significant, dose-dependent increases in standing systolic blood pressure with CuraAX (CST-3056) treatment in patients with symptomatic neurogenic orthostatic hypotension (nOH).